Kalluri HV, Rosebraugh MR, Misko TP, Ziemann A, et al. Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants. Ann Neurol 2023;93:285-296.
PMID: 36093738